NMS Group, the leading group providing complete and innovative oncology solution, has announced the merger by incorporation of CLIOSS S.r.l. (Clinical Organization for Strategies & Solotions S.r.l.) into NMS S.r.l. (Nerviano Medical Sciences S.r.l.), both 100% owned by the Group, effective from December 31st, 2019.
The deal was approved by the Board of Directors of Nerviano Medical Sciences S.r.l., pursuant to Articles 2501-ter and 2505 of the Italian Civil Code and the company bylaws. The merger was subsequently approved at shareholder meetings of the two companies.
The merger aims at concentrating the resources and expertise of CLIOSS to accelerate the product development process of NMS. The decision is in line with the Group’s strategy to increase synergy and provide an integrated solution. For further information on the transaction, please refer to the press releases and all the other documents publicly available at the NMS Group website and the CCIAA (Camera di Commercio, Industria, Artigianato e Agricoltura) registration office.